Sven Erik Nørholt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sven Erik Nørholt has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Anders Kjellman
Department of Clinical Science, Intervention and Technology, Division of Urology, Karolinska Institute, Stockholm, Sweden; Department of Urology, Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden
1 shared publication Anthony Glennane
Clinical Development, Amgen, Inc Thousand Oaks California
1 shared publication- Bente Brokstad Herlofson
Faculty of Dentistry, University of Oslo, Oslo, Norway
1 shared publication - Bruna Neves de Freitas
Department of Dentistry and Oral Health, Aarhus University, Aarhus, Denmark
1 shared publication - Cecilia Larsson Wexell
Department of Oral and Maxillofacial Surgery, Public Dental Service, Region Västra Götaland, SÄS, Borås, Sweden
1 shared publication - Flemming Isidor
Department of Dentistry and Oral Health, Section for Prosthodontics, Aarhus University, Aarhus, Denmark
1 shared publication
Latest Publications
- Open Access
Dental teachers’ perspectives on Extended Reality in dental education: an international survey
Introduction: Digital technologies are reshaping how health professionals are trained, and extended reality (XR) has gained attention as a tool for skills development in dental education. Yet, successful integration depends largely on educators’ perceptions, readiness, and working conditions. This study aimed to explore dental educators’ views of the educational value of XR, what barriers they experience, and how familiarity with immersive technologies relates to their use in teaching. Materials and Methods: A cross-sectional, web-based survey was conducted among dental educators. The questionnaire included items on demographics, familiarity and frequency of XR use, and perceptions of educational value, barriers, and curricular integration. Descriptive statistics were calculated, and Spearman correlation analyses were performed to explore associations between familiarity, use, and perceived benefits of XR. Results: Respondents reported positive attitudes toward XR, particularly for improving students’ understanding of complex anatomy (mean = 6.02/7), skill development (5.68/7), and confidence and preparedness for clinical practice (5.08-5.20/7). XR was mainly viewed as a complement to traditional teaching rather than a replacement (mean = 3.77/7). Strong correlations were observed between perceived improvements in confidence, skills, and clinical readiness (r = 0.71 - 0.89, P < 0.0001). High costs, limited technical support, and time constraints were the most prominent barriers to usage. Conclusion: Overall, dental educators appear open to XR but constrained by structural and organizational factors rather than a lack of interest. Faculty development, hands-on training opportunities, and institutional support may therefore be essential to translating positive perceptions into meaningful and sustained integration of immersive technologies in dental curricula.
Open AccessDental teachers’ perspectives on Extended Reality in dental education: an international survey
Introduction: Digital technologies are reshaping how health professionals are trained, and extended reality (XR) has gained attention as a tool for skills development in dental education. Yet, successful integration depends largely on educators’ perceptions, readiness, and working conditions. This study aimed to explore dental educators’ views of the educational value of XR, what barriers they experience, and how familiarity with immersive technologies relates to their use in teaching. Materials and Methods: A cross-sectional, web-based survey was conducted among dental educators. The questionnaire included items on demographics, familiarity and frequency of XR use, and perceptions of educational value, barriers, and curricular integration. Descriptive statistics were calculated, and Spearman correlation analyses were performed to explore associations between familiarity, use, and perceived benefits of XR. Results: Respondents reported positive attitudes toward XR, particularly for improving students’ understanding of complex anatomy (mean = 6.02/7), skill development (5.68/7), and confidence and preparedness for clinical practice (5.08-5.20/7). XR was mainly viewed as a complement to traditional teaching rather than a replacement (mean = 3.77/7). Strong correlations were observed between perceived improvements in confidence, skills, and clinical readiness (r = 0.71 - 0.89, P < 0.0001). High costs, limited technical support, and time constraints were the most prominent barriers to usage. Conclusion: Overall, dental educators appear open to XR but constrained by structural and organizational factors rather than a lack of interest. Faculty development, hands-on training opportunities, and institutional support may therefore be essential to translating positive perceptions into meaningful and sustained integration of immersive technologies in dental curricula.
- Open Access
- 15 July 2025
- Published by Elsevier in International Journal of Oral and Maxillofacial Surgery
- Vol. 55 (3) , 333-340
Robotic-controlled laser osteotome versus manually controlled osteotomy for interdental osteotomies: a cadaveric study
- 15 July 2025
- Published by Elsevier in International Journal of Oral and Maxillofacial Surgery
- Vol. 55 (3) , 333-340
Open AccessRobotic-controlled laser osteotome versus manually controlled osteotomy for interdental osteotomies: a cadaveric study
- Open Access
Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator‐mandated cohort postauthorization safety study in Denmark, Norway, and Sweden
BACKGROUND: Osteonecrosis of the jaw (ONJ) is an adverse effect of antiresorptive treatment. This study estimated incidence proportions and incidence rates of ONJ in cancer patients with bone metastases from solid tumors treated for the prevention of skeletal‐related events in routine clinical practice.METHODS: This cohort study in Denmark, Norway, and Sweden in 2011‐2018 included 3 treatment cohorts: a denosumab inception cohort (DEIC), a zoledronic acid inception cohort (ZAIC), and a denosumab‐switch cohort (DESC). The authors estimated 1‐ to 5‐year incidence proportions and incidence rates of ONJ overall, by cancer site (breast, prostate, or other solid tumor), and by country. ONJ diagnoses were confirmed by adjudication.RESULTS: There were 1340 patients in the DEIC, 1352 in the ZAIC, and 408 in the DESC. The median ages of the 3 cohorts were 70, 69, and 70 years, respectively; the proportions of men were 72.6%, 53.8%, and 48.3%, respectively; and the median follow‐up was 19.8, 12.9, and 13.3 months, respectively. The 5‐year incidence proportions of ONJ were 5.7% (95% confidence interval [CI], 4.4%‐7.3%) in the DEIC, 1.4% (95% CI, 0.8%‐2.3%) in the ZAIC, and 6.6% (95% CI, 4.2%‐10.0%) in the DESC. The corresponding ONJ incidence rates per 100 person‐years were 3.0 (95% CI, 2.3‐3.7), 1.0 (95% CI, 0.6‐1.5), and 4.3 (95% CI, 2.8‐6.3). Incidence proportions and incidence rates were highest in patients with prostate cancer and in Denmark.CONCLUSIONS: This study provides estimates of the risk of medically confirmed ONJ among patients initiating denosumab or zoledronic acid in routine clinical practice in 3 Scandinavian countries. The results varied by cancer site and by country.LAY SUMMARY: Denosumab and zoledronic acid reduce the risk of bone fractures, pain, and surgery in patients with advanced cancers involving bone. Osteonecrosis of the jaw (ONJ)—death of a jawbone—is a known side effect of treatment with denosumab or zoledronic acid. The authors examined almost 2900 denosumab‐ or zoledronic acid–treated patients with cancer in Denmark, Norway, and Sweden. Over the course of 5 years, ONJ developed in 5.7% of the patients whose initial treatment was denosumab, in 1.4% of the patients whose initial treatment was zoledronic acid, and in 6.6% of the patients who switched from zoledronic acid to denosumab.
Open AccessOsteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator‐mandated cohort postauthorization safety study in Denmark, Norway, and Sweden
BACKGROUND: Osteonecrosis of the jaw (ONJ) is an adverse effect of antiresorptive treatment. This study estimated incidence proportions and incidence rates of ONJ in cancer patients with bone metastases from solid tumors treated for the prevention of skeletal‐related events in routine clinical practice.METHODS: This cohort study in Denmark, Norway, and Sweden in 2011‐2018 included 3 treatment cohorts: a denosumab inception cohort (DEIC), a zoledronic acid inception cohort (ZAIC), and a denosumab‐switch cohort (DESC). The authors estimated 1‐ to 5‐year incidence proportions and incidence rates of ONJ overall, by cancer site (breast, prostate, or other solid tumor), and by country. ONJ diagnoses were confirmed by adjudication.RESULTS: There were 1340 patients in the DEIC, 1352 in the ZAIC, and 408 in the DESC. The median ages of the 3 cohorts were 70, 69, and 70 years, respectively; the proportions of men were 72.6%, 53.8%, and 48.3%, respectively; and the median follow‐up was 19.8, 12.9, and 13.3 months, respectively. The 5‐year incidence proportions of ONJ were 5.7% (95% confidence interval [CI], 4.4%‐7.3%) in the DEIC, 1.4% (95% CI, 0.8%‐2.3%) in the ZAIC, and 6.6% (95% CI, 4.2%‐10.0%) in the DESC. The corresponding ONJ incidence rates per 100 person‐years were 3.0 (95% CI, 2.3‐3.7), 1.0 (95% CI, 0.6‐1.5), and 4.3 (95% CI, 2.8‐6.3). Incidence proportions and incidence rates were highest in patients with prostate cancer and in Denmark.CONCLUSIONS: This study provides estimates of the risk of medically confirmed ONJ among patients initiating denosumab or zoledronic acid in routine clinical practice in 3 Scandinavian countries. The results varied by cancer site and by country.LAY SUMMARY: Denosumab and zoledronic acid reduce the risk of bone fractures, pain, and surgery in patients with advanced cancers involving bone. Osteonecrosis of the jaw (ONJ)—death of a jawbone—is a known side effect of treatment with denosumab or zoledronic acid. The authors examined almost 2900 denosumab‐ or zoledronic acid–treated patients with cancer in Denmark, Norway, and Sweden. Over the course of 5 years, ONJ developed in 5.7% of the patients whose initial treatment was denosumab, in 1.4% of the patients whose initial treatment was zoledronic acid, and in 6.6% of the patients who switched from zoledronic acid to denosumab.
- 4 February 2019
- Published by Wiley in Clinical Oral Implants Research
- Vol. 30 (3) , 277-284
Cone beam computed tomography evaluation of staged lateral ridge augmentation using platelet‐rich fibrin or resorbable collagen membranes in a randomized controlled clinical trial
Objectives: To evaluate the volumetric changes following lateral alveolar ridge augmentation using autogenous bone graft covered by either a platelet‐rich fibrin membrane (test group) or an inorganic bovine bone substitute and a resorbable collagen barrier membrane (control group).Material and methods: A total of 27 partially edentulous patients (test n = 14, control n = 13) with the indication for lateral bone block augmentation were included in this randomized, controlled clinical trial. Cone beam computed tomography (CBCT) examination was performed prior to grafting and 2 weeks and 6 months after grafting. The volumetric changes between the various examinations times were evaluated by planimetric measurements on two‐dimensional CBCT images of the grafted regions.Results: The mean bone volumetric loss in the test group was 14.7%, SD ±8.9%, while the mean bone volume loss in the control group was 17.8%, SD ±13.3%. This difference was not significant (p = 0.48). A total of ten patients were operated in the incisor and canine region with a mean bone volume loss of 23.41% SD, ±10.87%, while 17 patients were operated in the premolar region with a mean bone volume loss of 11.89% SD ±9.05%. This difference was significant (p = 0.01).Conclusion: The test and control group demonstrated no overall difference in volumetric bone changes of the augmented bone at the 6‐month follow‐up. The second major finding revealed a significantly larger amount of bone resorption in the incisor and canine region than in the premolar region of the maxilla, particularly in the control group.
- 4 February 2019
- Published by Wiley in Clinical Oral Implants Research
- Vol. 30 (3) , 277-284
Cone beam computed tomography evaluation of staged lateral ridge augmentation using platelet‐rich fibrin or resorbable collagen membranes in a randomized controlled clinical trial
Objectives: To evaluate the volumetric changes following lateral alveolar ridge augmentation using autogenous bone graft covered by either a platelet‐rich fibrin membrane (test group) or an inorganic bovine bone substitute and a resorbable collagen barrier membrane (control group).Material and methods: A total of 27 partially edentulous patients (test n = 14, control n = 13) with the indication for lateral bone block augmentation were included in this randomized, controlled clinical trial. Cone beam computed tomography (CBCT) examination was performed prior to grafting and 2 weeks and 6 months after grafting. The volumetric changes between the various examinations times were evaluated by planimetric measurements on two‐dimensional CBCT images of the grafted regions.Results: The mean bone volumetric loss in the test group was 14.7%, SD ±8.9%, while the mean bone volume loss in the control group was 17.8%, SD ±13.3%. This difference was not significant (p = 0.48). A total of ten patients were operated in the incisor and canine region with a mean bone volume loss of 23.41% SD, ±10.87%, while 17 patients were operated in the premolar region with a mean bone volume loss of 11.89% SD ±9.05%. This difference was significant (p = 0.01).Conclusion: The test and control group demonstrated no overall difference in volumetric bone changes of the augmented bone at the 6‐month follow‐up. The second major finding revealed a significantly larger amount of bone resorption in the incisor and canine region than in the premolar region of the maxilla, particularly in the control group.
- 1 March 2013
- Published by Elsevier in International Journal of Oral and Maxillofacial Surgery
- Vol. 42 (3) , 329-336
Functional changes following distraction osteogenesis treatment of asymmetric mandibular growth deviation in unilateral juvenile idiopathic arthritis: a prospective study with long-term follow-up
- 1 March 2013
- Published by Elsevier in International Journal of Oral and Maxillofacial Surgery
- Vol. 42 (3) , 329-336
Functional changes following distraction osteogenesis treatment of asymmetric mandibular growth deviation in unilateral juvenile idiopathic arthritis: a prospective study with long-term follow-up